Page Comparison

Drs. Lynn Wecker PhD and Michelle Mattingly PhD

Understanding the basis for differences in both drug responses and psychosocial therapies forms the basis for treatment selection in psychiatric disorders. This course will explore and expand knowledge and applications of (a) why specific medications may have either a therapeutic benefit treatment emergent adverse effect for some, but not all individuals; (b) genetic polymorphisms of neurotransmitter-associated proteins including enzymes, transporters and receptors that mediate chemical neurotransmission, and the possible role of these alterations in the manifestation of behavioral disorders; (c) how psychosocial factors influence the manifestation of both positive and negative health related behaviors; and (d) the utility of empathy with patients and its impact on differential therapeutics inclusive of integrating pharmacotherapy and psychotherapy in optimal care.

Goals and Objectives

The goals and objectives of this course are to complement the basic and clinical information gained during their first three years of medical school and provide students a solid understanding of both pharmacogenomics and the behavioral aspects of patient care. Specifically, Pharmacogenomics and Psychosocial Aspects of Patient Care is designed (a) to provide an understanding of the interactions between genetic inheritance, drug actions and the body’s response to drugs; and, (b) to expand on personalized medicine and patient centered care that were previously learned or encountered by the medical student during the first three years in medical school. A working knowledge that psychiatric treatments (either psychopharmacological or psychosocial) can be tailor made and adapted to the individual is essential as these issues have implications for patient health, adherence to treatment and patient-physician relationship.

Teaching faculty

USF faculty of Psychiatry

Evaluation

Students will be evaluated based on faculty evaluation of interaction, participation, and presentation on a current issue in pharmacogenomics.

Track

One of the options for Emergency Medicine, Family Medicine, Psychiatry, and Pediatrics